Ascletis Pharma Inc. (HKG:1672)
8.94
-0.23 (-2.51%)
Jul 28, 2026, 4:08 PM HKT
Ascletis Pharma Revenue
In the year 2025, Ascletis Pharma had annual revenue of 2.03M CNY with 58.07% growth. Ascletis Pharma had revenue of 947.00K in the half year ending December 31, 2025, a decrease of -90.61%.
Revenue
2.03M CNY
Revenue Growth
+58.07%
P/S Ratio
4,204.51
Revenue / Employee
10.04K CNY
Employees
202
Market Cap
9.49B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.03M | 745.00K | 58.07% |
| Dec 31, 2024 | 1.28M | -55.31M | -97.73% |
| Dec 31, 2023 | 56.60M | 2.51M | 4.63% |
| Dec 31, 2022 | 54.09M | -22.79M | -29.64% |
| Dec 31, 2021 | 76.88M | 41.88M | 119.64% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Everest Medicines | 1.90B |
| HBM Holdings | 1.23B |
| Lepu Biopharma | 1.04B |
| Abbisko Cayman | 681.17M |
| Alphamab Oncology | 630.11M |
| Nanjing Leads Biolabs | 197.25M |
| Suzhou Ribo Life Science | 165.26M |
| GenFleet Therapeutics (Shanghai) | 144.96M |
Ascletis Pharma News
- 1 day ago - Ascletis Announces Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse Model - PRNewsWire
- 13 days ago - Ascletis Selects for Clinical Development a Fixed-Dose Combination of First-in-Class Oral Small Molecule GIPR Agonist, ASC48, and Oral Small Molecule GLP-1R Agonist, ASC30 - PRNewsWire
- 5 weeks ago - Ascletis Announces U.S. FDA IND Clearance for Phase I Study of Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for the Treatment of Obesity - PRNewsWire
- 7 weeks ago - Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39 - PRNewsWire
- 2 months ago - Ascletis to Present Data on Multiple Programs at the 33rd European Congress on Obesity (ECO 2026) - PRNewsWire
- 3 months ago - Ascletis to Present Data on Multiple Programs at the American Diabetes Association's 2026 Scientific Sessions - PRNewsWire
- 3 months ago - Ascletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes - PRNewsWire
- 4 months ago - Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development - PRNewsWire